This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.


This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.


This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Dose Check's dosing guidance is designed to simplify starting and titrating a new basal insulin.1,2 And supporting patients in using Dose Check and self-titrating, so they are on the right dose, may prevent long-term health complications.3, 5-8

Dose Check is a software developed to assist healthcare professionals and patients in the process of titration for selected Novo Nordisk insulins with the follow-up of the responsible healthcare professional. Dose Check does not make any type of diagnosis. It does not substitute the professional medical advice given by doctors, physicians or diabetes care teams.

Any healthcare professional can register free of charge through the Dose Check Dashboard in countries where Dose Check is available. You can access the Dose Check Dashboard via your PC or mobile phone browser.

Dose Check provides guidance for selected Novo Nordisk insulins. Please contact your local Novo Nordisk representative for more information.

Please contact your Novo Nordisk representative to ask if Dose Check is available in your respective country. Healthcare professionals need to register with Dose Check to gain access to the Dose Check Dashboard to set up patients and initiate use.

Novo Nordisk will not have access to data that enables identification of patients registered with Dose Check. All data that may identify a patient such as name, telephone number or date of birth is stored only by the legal manufacturer Amalgam and is not transferred to Novo Nordisk or any third party. For more information about data protection and data privacy, refer to the Dose Check Privacy Policy.

Reference not found

Digital Health Solutions

With our digital therapeutic technologies and device innovations, we aim to improve the health and well-being of people living with diabetes around the world.
Smart pens. Smarter Care

The smart insulin pens NovoPen® 6 & NovoPen Echo® Plus are designed to improve insulin dose recording. This may help HCPs to have informed discussions with diabetes patients based on individual injection data.11-13
Digital Health Partnerships

Get to know the ecosystem of Novo Nordisk’s digital health partners.


Data on file: Technical Specification Document & Device Description (DDSC-1) Amalgam Guide.


Dose Check Evidence Based Titration Protocols – Reference Document.


CER-001 – iSage Rx Clinical Evaluation Report Rev. 13.


Grdinovac, K et al. iSage: Successful Basal Insulin Titration Managed by a Prescription-Only Digital Therapy for T2DM. Diabetes 2019; 68: 122-LB.


Russell-Jones D et al. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab 2018; 20(3): 488–496.


UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837–53.


The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44(8): 968–83.


Stratton IM et al. Association of glycaemia with macrovascular and micovascular complications of type 2 diabetes (UKPDS 33). BMJ 2000; 321(7258): 405–12.


Curtis B, Lage MJ. Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study. J Med Econ 2014; 17: 21-31.


Berard L et al. Insights into optimal basal insulin titration in type 2 diabetes: Results of a quantitative survey. Diabetes Obes Metab 2018; 20: 301-308.


NovoPen® 6 & NovoPen Echo® Plus Design Specification / Verification Report (Data on File).


Klonoff DC et al. JDiabetes SciTechnol. 2018;12(3):551-553.


Peter Adolfsson et al. Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen. DIABETES TECHNOLOGY & THERAPEUTICS Volume 22, Number 10, 2020.